Umbilical cord blood cells capable of engrafting in primary, secondary, and tertiary xenogeneic hosts are preserved after ex vivo culture in a noncontact system
Open Access
- 1 June 2001
- journal article
- Published by American Society of Hematology in Blood
- Vol. 97 (11) , 3441-3449
- https://doi.org/10.1182/blood.v97.11.3441
Abstract
This report describes stroma-based and stroma-free cultures that maintain long-term engrafting hematopoietic cells for at least 14 days ex vivo. Umbilical cord blood (UCB) CD34+ cells were cultured in transwells above AFT024 feeders with fetal-liver-tyrosine-kinase (FL) + stem cell factor (SCF) + interleukin 7 (IL-7), or FL + thrombopoietin (Tpo). CD34+ progeny were transplanted into nonobese diabetic-severe combined immunodeficiency (NOD-SCID) mice or preimmune fetal sheep. SCID repopulating cells (SRC) with multilineage differentiation potential were maintained in FL-SCF-IL-7 or FL-Tpo containing cultures for up to 28 days. Marrow from mice highly engrafted with uncultured or expanded cells induced multilineage human hematopoiesis in 50% of secondary but not tertiary recipients. Day 7 expanded cells engrafted primary, secondary, and tertiary fetal sheep. Day 14 expanded cells, although engrafting primary and to a lesser degree secondary fetal sheep, failed to engraft tertiary recipients. SRC that can be transferred to secondary recipients were maintained for at least 14 days in medium containing glycosaminoglycans and cytokines found in stromal supernatants. This is the first demonstration that ex vivo culture in stroma-noncontact and stroma-free cultures maintains “long-term” engrafting cells, defined by their capacity to engraft secondary or tertiary hosts.Keywords
This publication has 37 references indexed in Scilit:
- Multi-lineage expansion potential of primitive hematopoietic progenitors: Superiority of umbilical cord blood compared to mobilized peripheral bloodExperimental Hematology, 2000
- Abrogation of post-myeloablative chemotherapy neutropenia by ex-vivo expanded autologous CD34-positive cellsThe Lancet, 1999
- No Discrepancy between in Vivo Gene Marking Efficiency Assessed in Peripheral Blood Populations Compared with Bone Marrow Progenitors or CD34+ CellsHuman Gene Therapy, 1999
- Dependence of Human Stem Cell Engraftment and Repopulation of NOD/SCID Mice on CXCR4Science, 1999
- Cytokine treatment or accessory cells are required to initiate engraftment of purified primitive human hematopoietic cells transplanted at limiting doses into NOD/SCID miceBone Marrow Transplantation, 1999
- Outcomes among 562 Recipients of Placental-Blood Transplants from Unrelated DonorsNew England Journal of Medicine, 1998
- Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: Implications for gene therapyNature Medicine, 1996
- Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patientsThe Lancet, 1993
- Lymphohemopoietic reconstitution using wheat germ agglutinin-positive hemopoietic stem cell transplantation within but not across the major histocompatibility antigen barriers.Proceedings of the National Academy of Sciences, 1993
- The SCID-hu Mouse: Murine Model for the Analysis of Human Hematolymphoid Differentiation and FunctionScience, 1988